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Background: It is unclear whether antibodies can prevent Mycobacterium tuberculosis 
(Mtb) infection. In this study, we examined the relationship between total plasma IgG 
levels, IgG elicited by childhood vaccines and soil-transmitted helminths, and Mtb infec-
tion prevalence, defined by positive QuantiFERON (QFT) test.
Methods: We studied 100 Mtb uninfected infants, aged 4–6 months. Ten infants (10%) 
converted to positive QFT test (QFT+) within 2 years of follow-up for Mtb infection. 
Antibody responses in plasma samples acquired at baseline and tuberculosis inves-
tigation were analyzed by enzyme-linked immunosorbent assay and ImmunoCAP® 
assay.
results: QFT− infants displayed a significant increase in total IgG titers when 
re-tested, compared to IgG titers at baseline, which was not observed in QFT+ infants. 
Bacille Calmette-Guérin (BCG) vaccine-specific IgG2 and live-attenuated measles 
vaccine-specific IgG were raised in QFT− infants, and infants who acquired an Mtb 
infection did not appear to launch a BCG-specific IgG2 response. IgG titers against 
the endemic helminth Ascaris lumbricoides increased from baseline to QFT re-testing 
in all infants.
conclusion: These data show raised IgG associates with a QFT-status. Importantly, this 
effect was also associated with a trend showing raised IgG titers to BCG and measles 
vaccine. Our data suggest a possible protective association between raised antibody 
titers and acquisition of Mtb infection, potentially mediated by exposure to antigens both 
related and unrelated to Mtb.
Keywords: Mycobacterium tuberculosis infection, antibody, enzyme-linked immunosorbent assay, Bacille 
calmette-guérin, vaccine, helminth
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inTrODUcTiOn
Mycobacterium tuberculosis (Mtb) infection and tuberculosis (TB) 
disease represents one of the greatest global infectious disease bur-
dens (1). The only licensed TB vaccine, Bacille Calmette-Guérin 
(BCG), may partially protect against Mtb infection and provides 
protection against disseminated forms of active TB disease (2–5), 
but protection against pulmonary TB disease varies widely with 
age and mycobacterial exposure (6). Development of a vaccine 
that is more effective than BCG is crucial for the ultimate control 
of both Mtb infection and TB disease (7, 8).
Protection conferred by most clinically efficacious vaccines 
against their target pathogens requires a protective antibody 
response (9–11). Antibody responses against Mtb do correlate 
with, and may provide protection against, TB disease (12–17). 
However, there is no clinical evidence to support the hypothesis 
that an effective TB vaccine might be based on induction of an 
antibody response that controls Mtb infection.
Our current understanding of how antibodies could protect 
against Mtb infection or TB disease is limited, when compared 
with our understanding of, for example, T cell-driven immunity to 
Mtb. However, classical functions of antibody such as neutraliza-
tion, opsonization, and antibody-dependent cellular cytotoxicity 
(ADCC) have all been demonstrated to contribute to protective 
immunity against Mtb. Antibody opsonization can enhance Mtb 
uptake by (for example) macrophages (12–14), while both anti-
body neutralization (12, 13) and ADCC-mediated control of Mtb 
have been shown to inhibit bacterial growth (18). The intrinsic 
features of an antibody also contribute to their ability to control 
Mtb. For example, variation in immunoglobulin glycosylation can 
influence antibody-mediated control of bacterial replication (18). 
Different roles for antibody classes in the control of Mtb infection 
have also been demonstrated. In active TB disease, IgG has been 
shown to impair control and IgA enhance control of disease (19). 
Therefore, the full range of antibody functions can influence host 
immunity to Mtb, but whether these effects enhance or impede 
control of infection is likely to vary, depending on whether the 
host is responding to a latent infection or pathogenic disease.
Any antibody-mediated protection against Mtb may also 
be influenced by host vaccination status and/or history of co-
infections unrelated to Mtb. Childhood vaccinations, such as live 
attenuated measles, have been suggested to alter Mtb-associated 
immune responses (20, 21). Additionally, in Sub-Saharan Africa, 
the potential effect of common endemic infections, such as 
helminths, on immune responses to concurrent or subsequent 
Mtb infection is an important consideration due to the substantial 
overlap in prevalence of these diseases (22). Clear evidence exists 
that helminths can alter host immunity to Mtb (23, 24). However, 
our overall understanding of the influence of bystander antigen/
pathogen challenges and immunity to Mtb remains unclear, war-
ranting further investigation.
Our study participants live in a region endemic for both TB 
and soil-transmitted helminths (STH) (25). They receive routine 
Expanded Programme on Immunization (EPI) vaccinations, 
which provides a platform to investigate the potential interplay 
between vaccines, helminth exposure, and Mtb immunity. In this 
study, we addressed whether plasma antibody levels associate 
with risk of acquiring Mtb infection in infants. Additionally, we 
sought to identify if associations existed between exposure to 
both related and unrelated antigens/pathogens and altered risk 
of Mtb infection.
MaTerials anD MeThODs
study Participants
This is a sub-study of a double-blind, placebo-controlled 
efficacy trial of the MVA85A vaccine candidate, performed 
in the Western Cape Province of South Africa, and which 
has been described previously (7). Infants aged 4–6  months, 
who had received BCG vaccine within 7  days of birth, were 
enrolled. Inclusion criteria at baseline were a negative HIV 
enzyme-linked immunosorbent assay (ELISA) result; negative 
QuantiFERON-TB Gold In-tube (QFT) test (used to detect Mtb 
infection by measuring IFNγ responses to specific mycobacte-
rial proteins); and no known exposure to an adult with active 
TB disease. Infants were expected to have received all routine 
vaccinations, per the EPI schedule. The trial showed that 
MVA85A boost vaccination did not provide additional protec-
tion against Mtb infection or TB disease, compared to BCG 
vaccination alone in newborns (7). Therefore, this sub-study 
combines infants from the placebo and MVA85A arms in the 
same analysis. 112 infants were sequentially recruited into the 
sub-study at the time of TB investigation (Figure 1A). However, 
complete clinical data and sample sets were not collected for 
12 participants, thus leaving clinical data and samples from 
100 participants (89.29%) available for analysis in this study 
(Figure 1A).
The sub-study and the parent trial (C-020-485) were approved 
by the University of Cape Town Faculty of Health Sciences 
Human Research Ethics Committee (032/2010 and 291/2008 
respectively); and written informed consent was obtained from 
the infants’ parents or legal guardians prior to participation.
Mtb infection
Infants were followed up at 3-monthly intervals for symptoms 
consistent with TB disease, which if detected, triggered admis-
sion for standardized investigation, including QFT re-testing. 
Infants with symptoms of weight loss or failure to thrive would 
routinely receive empirical anthelmintic therapy, in addition to 
regular mass deworming campaigns. Information about prior 
anthelmintic therapy was not collected. Asymptomatic infants 
were admitted if an individual with TB disease became a new 
household contact (7). Plasma samples were analyzed at baseline 
and at admission for TB disease investigation (Figure 1B). One 
sample was analyzed per participant, per time-point. Mtb infec-
tion was defined by a single positive QFT test (i.e., interferon-
gamma release assay conversion) at the time of TB investigation. 
Infants who were QFT positive, but did not show evidence of 
probable or definite TB disease were classified as Mtb-infected. 
None of the infants, irrespective of QFT status, were diagnosed 
with active TB disease. Infants were stratified by QFT negative 
(Mtb-uninfected), and QFT positive (Mtb-infected) status in the 
subsequent analyses; none of the infants had active TB disease.
FigUre 1 | Infants recruited to the tuberculosis (TB)/helminth study. Infants enrolled in the MVA85A trial were randomly assigned to the placebo or MVA85A 
vaccination arms (a). 112 infants were recruited to the TB/helminth study; incomplete clinical data and sample sets were available for n = 12 infants, leaving 
n = 100 available for further analysis. Time-points of blood collection for QFT (QuantiFERON) (B) were at baseline, study day 336, at last scheduled visit and/or 
upon TB investigation. Per participant, serum was analyzed at baseline and upon TB investigation. The age range of infants at baseline was 4–6 months, and the 
age range at TB investigation was 8–39 months.
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antigen Preparation for elisa
Vaccine Antigens
Bacille Calmette-Guérin (Danish strain 1331, Statens Serum Institut, 
Denmark), live-attenuated measles (Rouvax, Sanofi Pasteur), and 
tetanus toxoid (Tetavax, Sanofi Pasteur) vaccines were reconstituted 
in 1× phosphate-buffered saline (PBS) to produce antigen stocks 
(500 µg/ml); aliquots of stocks were stored at −80°C until required.
Helminth Antigen
Whole Ascaris lumbricoides worms were treated with a 10× 
penicillin/streptomycin solution in 1× Amphotericin B (Thermo 
Fisher Scientific), following which they were washed in filter-
sterilized (FS) 1× PBS. Worm sections were then homogenized 
in FS 1× PBS and centrifuged to remove cellular debris. The 
protein concentration of the soluble fraction was measured and 
adjusted to a stock concentration. Aliquots of the stock solution 
were frozen at −80°C until required.
Non-Specific and Antigen-Specific ELISA
The coating IgG antibody used for the total IgG ELISAs was 
used at 1:5,000 (anti-human IgG Fc-specific; Sigma-Aldrich). 
All vaccine and helminth coating antigens were used at 5 µg/ml 
for antigen-specific IgG or 10  µg/ml for antigen-specific IgG 
subtypes. Initial plasma sample dilutions were 1:50 (total IgG) 
and 1:20 (antigen-specific), followed by serial 1:5 dilutions of 
the initial dilutions. Secondary IgG (Southern Biotech) was 
used at 1:1,000, and secondary IgG subtypes (Southern Biotech) 
were used at 1:500. All secondary antibodies were alkaline 
phosphatase-linked.
Antibody ELISAs were performed similarly to methods described 
previously (19, 26). Briefly, Nunc Immuno Maxisorp 96-well plates 
(Thermo Fisher Scientific) were coated with antibody or antigen 
and incubated at 37°C for 3 h, following which plates were blocked 
overnight at 4°C. Sample was added (50 μl/well) and plates were 
incubated at 4°C overnight. Secondary antibody was added (50 μl/
well) after which the reactions were developed using PNP substrate 
(Sigma Aldrich). Reactions were stopped with 1 M NaOH and plates 
read on a Versamax 96-well plate reader (Molecular Devices) at 
405 nm (492 nm reference filter). Arbitrary antibody responses were 
determined from sample titration curves (optical density vs. sample 
dilution) as previously described (27), enabling a relative assessment 
of antibody levels in serum. According to this analysis, antibody 
levels in certain samples and for certain antibody types fell below 
the detection limit and are observed at 0 on the y-axes. This does 
not preclude the possibility of specific antibody responses within 
those samples, but may require detection with a more sensitive assay.
immunocaP® Test
The ImmunoCAP® in  vitro assay was used to detect antigen-
specific IgE responses in serum samples and was used according 
to the manufacturer’s instructions. An Ascaris suum-derived anti-
gen that is cross-reactive with A. lumbricoides was used to detect 
antigen-specific IgE. Responses to this antigen are described as 
Ascaris specific.
FigUre 2 | Comparisons of tuberculosis (TB) investigation total IgG responses to baseline total IgG, age and QFT outcome. Total serum IgG in participants at 
baseline and upon TB investigation visit (n = 100) as measured by enzyme-linked immunosorbent assay (a). Total IgG titers vs. age in months at TB investigation 
(n = 97), with samples from QFT positive participants indicated in purple (B); overlaid are the line-of-best-fit and 95% confidence bands (dashed lines). Association 
between age at TB investigation and QFT result (c). Antibody titers are presented as log-transformed arbitrary values. The Wilcoxon matched-pairs signed rank test 
was used to assess significance of the comparison in (a), and the Mann–Whitney test was used to assess significance in (c). The Spearman correlation was used 
to assess the strength of the correlation in (B).
TaBle 1 | Infant sociodemographic and clinical characteristics at tuberculosis 
(TB) investigation.
N = 100
infant characteristics
Age—months [median (interquartile range—IQR)] 20 (16–25.63)
Gender (male) 45 (45%)
Weight at admission—kg [median (IQR)] 9.34 (8.26–10.29)
TB symptoms (e.g., weight loss and failure-to-thrive) YES 60 (60%)
Positive QuantiFERON 10 (10%)
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statistical analysis
Dot plot graphs are represented with the median and inter-
quartile range where appropriate. Antibody responses in 
matched sample pairs were compared using the Wilcoxon 
matched-pairs signed rank test; the Mann–Whitney test was 
utilized for the analysis of unpaired two-group data. Grouped 
analyses were investigated by the Kruskal–Wallis test, with the 
Dunn’s multiple comparison posttest used to compare all pairs 
of columns. Correlations were investigated using the Spearman 
correlation test. Where appropriate, analyses were two-tailed. 
Significance was accepted at p ≤ 0.05. Analyses of immunologi-
cal data were performed using the GraphPad Prism software 
(v. 5.03).
resUlTs
cohort Description
The median age of infants at TB investigation was 20  months 
(interquartile range 16–25.63 months). Of the 100 infants ana-
lyzed, 10 (10%) tested QFT positive upon re-testing (Table 1).
infants Displayed an age-related increase 
in Total igg Titers
Analysis of total IgG titers revealed a significant increase in total 
IgG detected at the TB investigation visit, when compared to 
baseline (Figure 2A). At TB investigation, total IgG titers showed 
a clear bimodal distribution approximately around the median; 
further analysis revealed a significant reduction in detected total 
IgG in older participants (Figure 2B). No significant difference 
in the median age between QFT− and QFT+ participants was 
found (median age in months 20 vs. 23, respectively; p = 0.14) 
(Figure 2C).
Total igg Titers increase significantly  
in QFT negative infants
At baseline, infants who did or did not progress to Mtb infection had 
similar total IgG titers (Figure 3A). Analysis of total IgG responses at 
TB investigation revealed that infants who remained QFT− showed 
significant increases in total IgG titers from baseline compared to 
infants who became Mtb-infected (QFT+) (Figure 3A). However, 
there was no significant difference in total IgG titers between the 
QFT− and QFT+ groups at TB investigation (Figure 3A).
Furthermore, longitudinal analysis of infant IgG responses at 
baseline and at TB investigation showed significantly increased 
total IgG titers compared to baseline in infants who remained 
QFT− on the level of individual participants (Figure 3B). Infants 
who were QFT+ at TB investigation did not demonstrate signifi-
cant increases in total IgG (Figure 3B).
The potential influence on total IgG responses of vaccination 
with MVA85A or placebo (Candin®) was also addressed. In agree-
ment with data presented in Figure 3A, we found no significant 
differences in total IgG between placebo and MVA85A vaccinated 
FigUre 3 | Total IgG titers stratified by QFT outcome and MVA vaccination status. Relationship between QFT outcome and total IgG titers from baseline and 
tuberculosis (TB) investigation participant samples (a). A before/after comparison of samples subdivided as in (a) is presented in (B). Relationship between QFT 
outcome, MVA85A vaccination status, and total IgG titers from baseline and TB investigation participant samples (c). Column sample numbers left-right (c): 45, 4, 
45, 6, 45, 4, 45, 6. Antibody titers are presented as arbitrary values. Statistical analysis was performed with the Kruskal–Wallis test and Dunn’s post hoc test to 
assess significance of the comparisons in (a,c). The Wilcoxon matched-pairs signed rank test was used to assess significance of the associations in (B).
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study participants at baseline or TB investigation. Moreover, no 
differences were found in IgG titers between QFT− or QFT+ 
placebo and MVA85A vaccinated infants (Figure 3C).
QFT− status and Vaccine-specific igg 
titers after Bcg and Measles Vaccination
We next tested whether QFT status associated with antibody 
responses to BCG or to heterologous antigens. Antigen-specific 
antibody responses to BCG, live-attenuated measles, and tetanus 
toxoid vaccines were also measured at TB investigation and 
compared to infant Mtb infection outcome. Analysis of IgG 
responses to BCG, measles, and tetanus toxoid revealed a trend 
for increased measles-specific IgG titers (p = 0.08) in infants who 
did not acquire Mtb infection, but no association between BCG 
or tetanus toxoid IgG and Mtb infection outcome (Figure 4A). 
Analysis of BCG IgG subtype-specific responses revealed a trend 
for increased BCG-specific IgG2 titers (p = 0.08) in infants who 
did not acquire Mtb infection, but no association between BCG-
specific IgG1 or IgG3 and Mtb infection outcome (Figure 4B). 
This finding was related to significant inverse correlations 
between measles-specific IgG and quantitative QFT values, and 
between BCG-specific IgG2 and quantitative QFT values (Figures 
S1A,B in Supplementary Material). No associations were found 
with BCG-specific IgG/IgG1/IgG3 or tetanus-specific IgG titers 
and quantitative QFT values (Figures S1C–F in Supplementary 
Material). However, it is important to note that all participants 
who had Mtb infection but not disease had low levels of detect-
able IFNγ. As expected (28), tetanus toxoid-specific IgG titers 
significantly correlated with age at follow-up (Figure S2F in 
Supplementary Material). No relationship with age was found 
with anti-BCG or live-attenuated measles IgG titers at follow-up 
(Figure S2 in Supplementary Material).
soil-Transmitted helminth-specific igg 
Titers Were similar in QFT− and QFT+ 
infants
Since helminth exposure can alter risk and outcome of Mtb disease 
(29–31), we examined if any relationship existed between infant 
exposure to A. lumbricoides and Mtb infection. Of 91 stool sam-
ples obtained, none tested positive for active helminth infection 
(Table S1 in Supplementary Material). However, anti-Ascaris IgE 
and IgG, indicative of prior exposure to the parasite, were found 
in infants (Figure  5A). At TB investigation, 2/50 (4%) infants 
tested for IgE responses presented with raised Ascaris-specific 
IgE, as detected by ImmunoCAP® (Figure  5A). Additionally, 
85/100 (85%) infants at baseline and all infants at TB investigation 
had detectable anti-A. lumbricoides IgG, with these levels increas-
ing significantly from baseline to TB investigation (Figure 5A). 
Analysis of IgG subtype responses revealed that 6/100 (6%) 
infants at baseline and 48/100 (48%) infants at TB investigation 
had detectable levels of anti-A. lumbricoides IgG4 (Figure 5A). 
Anti-A. lumbricoides IgG nor IgG4 titers were not significantly 
different between QFT− infants and QFT+ infants (Figure 5B).
Longitudinal analysis of individual infant anti-A. lumbricoides 
IgG responses at baseline and TB investigation showed signifi-
cantly increased total IgG titers in both QFT− and QFT+ infants, 
FigUre 4 | Antibody responses at tuberculosis investigation to childhood vaccines. Anti-Bacille Calmette-Guérin (BCG), measles, and tetanus IgG titers  
(a), as well as anti-BCG IgG1, IgG2, and IgG3 titers (B) as measured by enzyme-linked immunosorbent assay and stratified by QFT result. One sample was 
excluded in the anti-measles IgG analysis (a) (participants had not received measles vaccination). Two fewer samples reported for BCG IgG1 (B) due to a lack  
of sample availability. Antibody titers are presented as arbitrary values. Comparisons were assessed for significance by the Mann–Whitney test.
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indicating an increase in anti-A. lumbricoides IgG responses over 
time (Figure 5C). Others have suggested that helminth infection 
negatively influences the magnitude of the QFT IFNγ response, 
resulting in a higher likelihood of an indeterminate result (32, 33). 
Although no association was found between anti-A. lumbricoides 
IgG and quantitative IFNγ in the same samples (as detected by 
QFT), a significant inverse correlation was found between anti-
A. lumbricoides IgG4 and quantitative IFNγ levels (Figure S3 in 
Supplementary Material).
DiscUssiOn
In this study, we found that infants who did not acquire Mtb 
infection had significantly increased total IgG titers from baseline 
to TB investigation, unlike infants who became Mtb infected. This 
effect was related to a trend showing raised IgG titers against BCG 
and measles vaccination. Together, these findings suggest that 
raised specific and heterologous IgG titers may play a role in host 
responses that protect against Mtb infection. Therefore, induction 
of protective IgG responses in QFT− infants may be a feature 
of immune activation by both pathogen-related and unrelated 
antigens.
Initial findings indicate that total IgG responses increase 
significantly from baseline to TB investigation; however, at TB 
investigation, there was an inverse correlation between total IgG 
titers and age. It is important to note that the total IgG titers 
presented are from two distinct age ranges, namely 4–6 months at 
baseline and 8–39 months at TB investigation, and that the range 
of antibody titer values is wide. Additionally, older infants tend 
FigUre 5 | Soil-transmitted helminth-specific IgG titers and QFT outcome at baseline and upon tuberculosis investigation. Anti-Ascaris lumbricoides IgE (n = 50), 
IgG, and IgG4 (n = 100) titers (a). Anti-A. lumbricoides IgG and IgG4 titers stratified by QFT outcome (B). A before/after comparison of anti-A. lumbricoides IgG 
titers as subdivided in (B) is presented in (c). Antibody titers are presented as arbitrary values. The Mann–Whitney test was used to assess two-group comparisons 
for significance in (a), the Kruskal–Wallis test with Dunn’s post hoc test was used for the multi-group comparisons in (B), and the Wilcoxon matched-pairs signed 
rank test was used to assess for significance in (c).
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to fall within the lower half of the bimodal sample distribution 
observed at TB investigation, indicating why an inverse correla-
tion between age and antibody titer is possible despite a higher 
median total IgG titer at TB investigation than at baseline.
Our findings build on recent reports demonstrating that 
antibody responses differentially contribute to control of Mtb 
infection and disease. Studies have addressed Mtb antigen-
specific immunoglobulin responses as contributing to a range of 
classical antibody-mediated responses (18, 19). In this study, we 
observed that only QFT− infants showed a significant increase in 
total IgG titers from baseline to TB investigation, suggesting an 
association between raised IgG and reduced risk of Mtb infection, 
highlighting the potential importance of antibodies in protective 
responses against Mtb.
It has long been known that BCG vaccination stimulates 
Mycobacterium-specific antibody production (34–36). Induction 
of IgM and IgG has been observed, with IgG1, IgG2, and IgG3 as 
the most prevalent IgG subtypes detected (37, 38). Our identifica-
tion of BCG-induced antibody responses in this study supports 
these previous studies. Our findings also suggest that infants 
who became Mtb infected did not launch a BCG-specific IgG2 
response, which could indicate some impairment of the humoral 
response to BCG vaccination in these infants, which in turn 
may be implicated in increased susceptibility to Mtb infection. 
However, the current study lacks sufficient participant numbers 
and power to address this question adequately and a larger cohort 
study would be required to analyze the importance of this finding. 
Nevertheless, to the best of our knowledge, this observation is 
novel and warrants further investigation.
We also identified a trend toward increased measles vac-
cine-specific IgG titers in QFT− infants as compared to QFT+ 
infants. However, since this difference was not statistically 
8Logan et al. Infant Mtb Infection and Antibodies
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significant, the possibility that measles vaccination might 
provide heterologous protection against acquisition of Mtb 
infection remains speculative. Measles vaccination has previ-
ously been shown to decrease responsiveness to the tuberculin 
skin test in individuals with a positive reaction to purified 
protein derivative and/or active TB disease (20, 21). Conversely 
others have suggested that certain childhood vaccines, such as 
measles (and BCG), may provide protection against all-cause 
mortality (39, 40).
We acknowledge that generalizability of the abovementioned 
results is limited by the sample size and that other infections at the 
time of TB investigation may have contributed to total IgG titers. 
However, it is unlikely that other infections would contribute 
differentially to IgG titers in QFT+ vs. QFT− children, or to 
BCG-specific or measles vaccine-specific antibody titers.
We found no association between anti-A. lumbricoides IgG 
or IgG4 responses and Mtb infection, suggesting that anti-
helminth responses do not underlie the differences observed 
with the total IgG responses in this cohort. Our current under-
standing of how helminth infection/exposure may influence 
Mtb infection is incomplete. Rodent studies have presented 
evidence of positive (23), neutral (41–43) and negative effects 
(30, 44) on host control of Mtb infection by helminths. Clinical 
reports of the relationship between helminth and Mtb infec-
tions are also not consistent, which is likely to reflect the 
diverse contexts of both helminth or Mtb infection/disease. 
Similar studies to ours also did not identify positive or negative 
associations between helminth exposure and Mtb infection or 
BCG efficacy (45–47).
We found that few infants had raised anti-A. lumbricoides IgE, 
in agreement with reports by others that anti-Ascaris IgE is pri-
marily detected in older children and IgG4 is primarily detected 
in younger children (48). We propose that the raised levels of anti-
A. lumbricoides IgG we observed are reflective of prior exposure 
to helminths. The unexpectedly low levels of current infection 
(25) may be attributable to appropriate household sanitation, 
water provision (Table S1 in Supplementary Material), and mass 
de-worming campaigns in the study community. Regardless, 
infants in this study showed evidence of immunological memory 
to helminth infection.
This study did not address antibody responses to Mtb-specific 
antigens due to a lack of antigen availability, and limited samples 
could not be used to optimize functional assays for more in-depth 
analysis of antibody responses. It is also important to consider 
the impact that small sample size may have had on the findings 
presented here. Despite a 2-year cumulative incidence of Mtb 
infection of 10%, the number of infants in the study who dem-
onstrated QFT conversion was small. A larger sample size would 
be required to investigate these initial findings more thoroughly. 
Notably, antigen-specific antibody responses and their associa-
tion with Mtb infection and/or TB disease have been investigated 
in a similar cohort; here, antigen 85A-specfic IgG responses were 
associated with a difference in the occurrence of TB disease, but 
not Mtb infection (15). However, a direct comparison between 
studies would be inaccurate due to the difference in antigen 
specificity and design of the assays, as well as the discrepancy in 
sample size between studies.
The data presented here suggest that both pathogen 
related and heterologous immune activation of the immature 
immune system by childhood vaccination may be implicated 
in reduced risk of acquiring an Mtb infection. The central find-
ing that infants who did not acquire Mtb infection exhibited 
significantly increased total IgG titers from baseline to the 
time of TB investigation warrants further investigation of the 
specific components of the total IgG response responsible for 
this observation.
eThics sTaTeMenT
This study was carried out in accordance with the recommenda-
tions of the University of Cape Town Faculty of Health Sciences 
Human Research Ethics Committee. The protocol was approved 
by the University of Cape Town Faculty of Health Sciences 
Human Research Ethics Committee. Written informed consent 
was obtained from the infants’ parents or legal guardians in 
accordance with the Declaration of Helsinki.
aUThOr cOnTriBUTiOns
AL, WH, and MH contributed to conceptualization and design 
of the study; EL performed experiments and data analysis; AL 
was the site investigator of the helminth study and analyzed 
clinical and sociodemographic data; MT and MH were principal 
investigators of the parent trial; HM was the study data manager; 
CO was the study coordinator; EL, TS, WH, and MH drafted the 
manuscript; EL, AL, DM, AC, MT, HS, WH, and MH contributed 
to manuscript revision and critical analysis.
acKnOWleDgMenTs
The authors would like to acknowledge and thank Professor 
Michael Levin (Red Cross War Memorial Children’s Hospital) 
for his provision of the A. lumbricoides worms used in this study, 
as well as the ImmunoCAP® testing for helminth-specific IgE 
responses. The authors would also like to acknowledge and thank 
the study participants, helminth-TB and 020 study teams for their 
contribution and data collection.
FUnDing
This work was supported by the EDCTP Senior Fellowship grant 
(TA.2009.40200.015) and the National Research Foundation 
(88939).
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
https://www.frontiersin.org/articles/10.3389/fimmu.2018.01529/
full#supplementary-material.
9Logan et al. Infant Mtb Infection and Antibodies
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1529
reFerences
1. WHO. Global Tuberculosis Report. Geneva: World Health Organization 
(2016).
2. Fine PE. Variation in protection by BCG: implications of and for heterologous 
immunity. Lancet (1995) 346(8986):1339–45. doi:10.1016/S0140-6736(95) 
92348-9 
3. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. 
The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants 
in the prevention of tuberculosis: meta-analyses of the published literature. 
Pediatrics (1995) 96(1 Pt 1):29–35. 
4. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al. 
Effect of BCG vaccination against Mycobacterium tuberculosis infection in chil-
dren: systematic review and meta-analysis. BMJ (2014) 349:g4643. doi:10.1136/ 
bmj.g4643 
5. Basu Roy R, Sotgiu G, Altet-Gomez N, Tsolia M, Ruga E, Velizarova S, et al. 
Identifying predictors of interferon-gamma release assay results in pediatric 
latent tuberculosis: a protective role of bacillus Calmette-Guerin? A pTB-
NET collaborative study. Am J Respir Crit Care Med (2012) 186:378–84. 
doi:10.1164/rccm.201201-0026OC 
6. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, et al. Protection 
by BCG vaccine against tuberculosis: a systematic review of randomized 
controlled trials. Clin Infect Dis (2014) 58(4):470–80. doi:10.1093/cid/ 
cit790 
7. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, 
et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants 
previously vaccinated with BCG: a randomised, placebo-controlled phase 2b 
trial. Lancet (2013) 381(9871):1021–8. doi:10.1016/S0140-6736(13)60177-4 
8. Andersen P, Kaufmann SH. Novel vaccination strategies against tuberculosis. 
Cold Spring Harb Perspect Med (2014) 4(6):1–20. doi:10.1101/cshperspect.
a018523 
9. Achkar JM, Casadevall A. Antibody-mediated immunity against tuberculosis: 
implications for vaccine development. Cell Host Microbe (2013) 13(3):250–62. 
doi:10.1016/j.chom.2013.02.009 
10. Siegrist C-A. Vaccine immunology. Vaccines (Basel) (2008) 5:1725. 
11. Robbins JB, Schneerson R, Szu SC. Hypothesis: how licensed vaccines confer 
protective immunity. Adv Exp Med Biol (1996) 397:169–82. doi:10.1007/ 
978-1-4899-1382-1_22 
12. de Valliere S, Abate G, Blazevic A, Heuertz RM, Hoft DF. Enhancement of 
innate and cell-mediated immunity by antimycobacterial antibodies. Infect 
Immun (2005) 73(10):6711–20. doi:10.1128/IAI.73.10.6711-6720.2005 
13. Chen T, Blanc C, Eder AZ, Prados-Rosales R, Souza AC, Kim RS, et  al. 
Association of human antibodies to arabinomannan with enhanced myco-
bacterial opsonophagocytosis and intracellular growth reduction. J Infect Dis 
(2016) 214(2):300–10. doi:10.1093/infdis/jiw141 
14. Kumar SK, Singh P, Sinha S. Naturally produced opsonizing antibodies restrict 
the survival of Mycobacterium tuberculosis in human macrophages by aug-
menting phagosome maturation. Open Biol (2015) 5(12):150171. doi:10.1098/
rsob.150171 
15. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, et al. T-cell 
activation is an immune correlate of risk in BCG vaccinated infants. Nat 
Commun (2016) 7:11290. doi:10.1038/ncomms11290 
16. Maglione PJ, Xu J, Casadevall A, Chan J. Fc gamma receptors regulate immune 
activation and susceptibility during Mycobacterium tuberculosis infection. 
J Immunol (2008) 180(5):3329–38. doi:10.4049/jimmunol.180.5.3329 
17. Teitelbaum R, Glatman-Freedman A, Chen B, Robbins JB, Unanue E, 
Casadevall A, et al. A mAb recognizing a surface antigen of Mycobacterium 
tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 
95(26):15688–93. doi:10.1073/pnas.95.26.15688 
18. Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, et al. A 
functional role for antibodies in tuberculosis. Cell (2016) 167(2):433–443.e14. 
doi:10.1016/j.cell.2016.08.072 
19. Zimmermann N, Thormann V, Hu B, Kohler AB, Imai-Matsushima A, 
Locht C, et  al. Human isotype-dependent inhibitory antibody responses 
against Mycobacterium tuberculosis. EMBO Mol Med (2016) 8(11):1325–39. 
doi:10.15252/emmm.201606330 
20. Mellman WJ, Wetton R. Depression of the tuberculin reaction by attenuated 
measles virus vaccine. J Lab Clin Med (1963) 61:453–8. 
21. Brody JA, Overfield T, Hammes LM. Depression of the tuberculin 
reaction by viral vaccines. N Engl J Med (1964) 271:1294–6. doi:10.1056/
NEJM196412172712505 
22. Hotez PJ, Mistry N, Rubinstein J, Sachs JD. Integrating neglected tropical 
diseases into AIDS, tuberculosis, and malaria control. N Engl J Med (2011) 
364(22):2086–9. doi:10.1056/NEJMp1014637 
23. du Plessis N, Kleynhans L, Thiart L, van Helden PD, Brombacher F, Horsnell WG, 
et al. Acute helminth infection enhances early macrophage mediated control of 
mycobacterial infection. Mucosal Immunol (2013) 6(5):931–41. doi:10.1038/
mi.2012.131 
24. Elias D, Akuffo H, Pawlowski A, Haile M, Schon T, Britton S. Schistosoma 
mansoni infection reduces the protective efficacy of BCG vaccination 
against virulent Mycobacterium tuberculosis. Vaccine (2005) 23(11):1326–34. 
doi:10.1016/j.vaccine.2004.09.038 
25. Hotez PJ, Kamath A. Neglected tropical diseases in sub-saharan Africa: review 
of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 
(2009) 3(8):e412. doi:10.1371/journal.pntd.0000412 
26. Cooper PJ, Espinel I, Wieseman M, Paredes W, Espinel M, Guderian RH, et al. 
Human onchocerciasis and tetanus vaccination: impact on the postvaccina-
tion antitetanus antibody response. Infect Immun (1999) 67(11):5951–7. 
27. Bobat S, Darby M, Mrdjen D, Cook C, Logan E, Auret J, et al. Natural and 
vaccine-mediated immunity to Salmonella typhimurium is impaired by the 
helminth Nippostrongylus brasiliensis. PLoS Negl Trop Dis (2014) 8(12):e3341. 
doi:10.1371/journal.pntd.0003341 
28. Borrow RBP, Roper MH. The Immunological Basis for Immunization Series. 
Module 3: Tetanus Update 2006. Switzerland: WHO (2007).
29. George PJ, Kumar NP, Sridhar R, Hanna LE, Nair D, Banurekha VV, et  al. 
Coincident helminth infection modulates systemic inflammation and 
immune activation in active pulmonary tuberculosis. PLoS Negl Trop Dis 
(2014) 8(11):e3289. doi:10.1371/journal.pntd.0003289 
30. Potian JA, Rafi W, Bhatt K, McBride A, Gause WC, Salgame P. Preexisting 
helminth infection induces inhibition of innate pulmonary anti-tuberculosis 
defense by engaging the IL-4 receptor pathway. J Exp Med (2011) 208(9): 
1863–74. doi:10.1084/jem.20091473 
31. Perry S, Hussain R, Parsonnet J. The impact of mucosal infections on acqui-
sition and progression of tuberculosis. Mucosal Immunol (2011) 4(3):246–51. 
doi:10.1038/mi.2011.11 
32. Lucas M, Nicol P, McKinnon E, Whidborne R, Lucas A, Thambiran A, 
et al. A prospective large-scale study of methods for the detection of latent 
Mycobacterium tuberculosis infection in refugee children. Thorax (2010) 
65(5):442–8. doi:10.1136/thx.2009.127555 
33. Thomas TA, Mondal D, Noor Z, Liu L, Alam M, Haque R, et al. Malnutrition 
and helminth infection affect performance of an interferon gamma-release 
assay. Pediatrics (2010) 126(6):e1522–9. doi:10.1542/peds.2010-0885 
34. Diena BB, Yugi H, Wallace R, Carriere J, Greenberg L. The bentonite floccula-
tion test in the serology of tuberculosis. I. Purification of BCG antigens. Can 
J Microbiol (1968) 14(8):881–5. doi:10.1139/m68-148 
35. Bardana EJ Jr, McClatchy JK, Farr RS, Minden P. Universal occurrence of 
antibodies to tubercle bacilli in sera from non-tuberculous and tuberculous 
individuals. Clin Exp Immunol (1973) 13(1):65–77. 
36. Parlett RC, Youmans GP. An evaluation of the specificity and sensitivity of a 
gel double-diffusion test for tuberculosis. Am Rev Respir Dis (1959) 80:153–66. 
37. Hoft DF, Kemp EB, Marinaro M, Cruz O, Kiyono H, McGhee JR, et al. A dou-
ble-blind, placebo-controlled study of Mycobacterium-specific human immune 
responses induced by intradermal bacille Calmette-Guerin vaccination. J Lab 
Clin Med (1999) 134(3):244–52. doi:10.1016/S0022-2143(99)90204-4 
38. Beyazova U, Rota S, Cevheroglu C, Karsligil T. Humoral immune response in 
infants after BCG vaccination. Tuber Lung Dis (1995) 76(3):248–53. doi:10.1016/ 
S0962-8479(05)80013-9 
39. Goodridge HS, Ahmed SS, Curtis N, Kollmann TR, Levy O, Netea MG, 
et al. Harnessing the beneficial heterologous effects of vaccination. Nat Rev 
Immunol (2016) 16(6):392–400. doi:10.1038/nri.2016.43 
40. Higgins JP, Soares-Weiser K, Lopez-Lopez JA, Kakourou A, Chaplin K, 
Christensen H, et  al. Association of BCG, DTP, and measles containing 
vaccines with childhood mortality: systematic review. BMJ (2016) 355:i5170. 
doi:10.1136/bmj.i5170 
41. Rafi W, Bhatt K, Gause WC, Salgame P. Neither primary nor memory 
immunity to Mycobacterium tuberculosis infection is compromised in mice 
10
Logan et al. Infant Mtb Infection and Antibodies
Frontiers in Immunology | www.frontiersin.org July 2018 | Volume 9 | Article 1529
with chronic enteric helminth infection. Infect Immun (2015) 83(3):1217–23. 
doi:10.1128/IAI.03004-14 
42. Hubner MP, Killoran KE, Rajnik M, Wilson S, Yim KC, Torrero MN, et al. 
Chronic helminth infection does not exacerbate Mycobacterium tuberculosis 
infection. PLoS Negl Trop Dis (2012) 6(12):e1970. doi:10.1371/journal.
pntd.0001970 
43. Frantz FG, Rosada RS, Turato WM, Peres CM, Coelho-Castelo AA, Ramos SG, 
et al. The immune response to toxocariasis does not modify susceptibility to 
Mycobacterium tuberculosis infection in BALB/c mice. Am J Trop Med Hyg 
(2007) 77(4):691–8. doi:10.4269/ajtmh.2007.77.691
44. Monin L, Griffiths KL, Lam WY, Gopal R, Kang DD, Ahmed M, et al. Helminth-
induced arginase-1 exacerbates lung inflammation and disease severity in 
tuberculosis. J Clin Invest (2015) 125(12):4699–713. doi:10.1172/JCI77378 
45. Biraro IA, Egesa M, Toulza F, Levin J, Cose S, Joloba M, et  al. Impact of 
co-infections and BCG immunisation on immune responses among house-
hold contacts of tuberculosis patients in a Ugandan cohort. PLoS One (2014) 
9(11):e111517. doi:10.1371/journal.pone.0111517 
46. Lule SA, Mawa PA, Nkurunungi G, Nampijja M, Kizito D, Akello F, et  al. 
Factors associated with tuberculosis infection, and with anti-mycobacterial 
immune responses, among five year olds BCG-immunised at birth in Entebbe, 
Uganda. Vaccine (2015) 33(6):796–804. doi:10.1016/j.vaccine.2014.12.015 
47. Ndibazza J, Mpairwe H, Webb EL, Mawa PA, Nampijja M, Muhangi L, et al. 
Impact of anthelminthic treatment in pregnancy and childhood on immunisa-
tions, infections and eczema in childhood: a randomised controlled trial. PLoS 
One (2012) 7(12):e50325. doi:10.1371/journal.pone.0050325 
48. Turner JD, Faulkner H, Kamgno J, Kennedy MW, Behnke J, Boussinesq M, et al. 
Allergen-specific IgE and IgG4 are markers of resistance and susceptibility in 
a human intestinal nematode infection. Microbes Infect (2005) 7(7–8):990–6. 
doi:10.1016/j.micinf.2005.03.036 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Logan, Luabeya, Mulenga, Mrdjen, Ontong, Cunningham, 
Tameris, McShane, Scriba, Horsnell and Hatherill. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) and the copyright owner are credited and that the original 
publication in this journal is cited, in accordance with accepted academic practice. 
No use, distribution or reproduction is permitted which does not comply with these 
terms.
